Mechanism of autoimmune hepatic fibrogenesis induced by an adenovirus encoding the human liver autoantigen cytochrome P450 2D6

Journal of Autoimmunity

Volumn 44, Issue , 2013, Pages 49-60

  Hintermann, Edith ^a   Ehser, Janine ^a   Bayer, Monika ^a   Pfeilschifter, Josef M ^a   Christen, Urs ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Adenoviral vectors; Autoimmune hepatitis; Cytochrome P450; Fibrosis; Liver immunology

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SMOOTH MUSCLE ACTIN; CYTOCHROME P450 2D6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE HEPATITIS TYPE 2; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROGENESIS; LIVER PARENCHYMA; MONOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STELLATE CELL;

EID: 84881373936     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.05.001     Document Type: Article

References (57)

1. Zeisberg M., Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol 2013, 304:C216-C225.
2. Friedman S.L. Liver fibrosis in 2012: convergent pathways that cause hepatic fibrosis in NASH. Nat Rev Gastroenterol Hepatol 2013, 10:71-72.
3. Czaja A.J., Manns M.P. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology 2010, 139:58-72.
4. Kocabayoglu P., Friedman S.L. Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci 2013, 5:217-230.
5. Iredale J.P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. JClin Invest 2007, 117:539-548.
6. Jiao J., Friedman S.L., Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009, 25:223-229.
7. Hirschfield G.M., Gershwin M.E. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 2013, 8:303-330.
8. Liberal R., Grant C.R., Mieli-Vergani G., Vergani D. Autoimmune hepatitis: a comprehensive review. JAutoimmun 2013, 41:126-139.
9. Gressner A.M., Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. JCell Mol Med 2006, 10:76-99.
10. Svegliati-Baroni G., De Minicis S., Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int 2008, 28:1052-1064.
11. Friedman S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008, 88:125-172.
12. Hinz B., Phan S.H., Thannickal V.J., Prunotto M., Desmouliere A., Varga J., et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012, 180:1340-1355.
13. Winau F., Quack C., Darmoise A., Kaufmann S.H. Starring stellate cells in liver immunology. Curr Opin Immunol 2008, 20:68-74.
14. Guyot C., Lepreux S., Combe C., Doudnikoff E., Bioulac-Sage P., Balabaud C., et al. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol 2006, 38:135-151.
15. Knittel T., Kobold D., Saile B., Grundmann A., Neubauer K., Piscaglia F., et al. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 1999, 117:1205-1221.
16. Iwaisako K., Brenner D.A., Kisseleva T. What's new in liver fibrosis? the origin of myofibroblasts in liver fibrosis. JGastroenterol Hepatol 2012, 27(Suppl. 2):65-68.
17. Manns M.P., Czaja A.J., Gorham J.D., Krawitt E.L., Mieli-Vergani G., Vergani D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010, 51:2193-2213.
18. Miksys S.L., Cheung C., Gonzalez F.J., Tyndale R.F. Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model. Drug Metab Dispos 2005, 33:1495-1502.
19. Christen U., Hintermann E., Jaeckel E. New animal models for autoimmune hepatitis. Semin Liver Dis 2009, 29:262-272.
20. Christen U., Holdener M., Hintermann E. Cytochrome P450 2D6 as a model antigen. Dig Dis 2010, 28:80-85.
21. Czaja A.J. Animal models of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol 2010, 4:429-443.
22. Hardtke-Wolenski M., Jaeckel E. Mouse models for experimental autoimmune hepatitis: limits and chances. Dig Dis 2010, 28:70-79.
23. Djilali-Saiah I., Lapierre P., Vittozi S., Alvarez F. DNA vaccination breaks tolerance for a neo-self antigen in liver: a transgenic murine model of autoimmune hepatitis. JImmunol 2002, 169:4889-4896.
24. Lapierre P., Djilali-Saiah I., Vitozzi S., Alvarez F. Amurine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology 2004, 39:1066-1074.
25. Toyonaga T., Hino O., Sugai S., Wakasugi S., Abe K., Shichiri M., et al. Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. Proc Natl Acad Sci U S A 1994, 91:614-618.
26. Hintermann E., Ehser J., Christen U. The CYP2D6 animal model: how to induce autoimmune hepatitis in mice. JoVE 2012, 60:1-7.
27. Holdener M., Hintermann E., Bayer M., Rhode A., Rodrigo E., Hintereder G., et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. JExp Med 2008, 205:1409-1422.
28. Ehser J., Holdener M., Christen S., Bayer M., Pfeilschifter J.M., Hintermann E., et al. Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis. JAutoimmun 2013, 39-49.
29. Proell V., Mikula M., Fuchs E., Mikulits W. The plasticity of p19 ARF null hepatic stellate cells and the dynamics of activation. Biochim Biophys Acta 2005, 1744:76-87.
30. Karlmark K.R., Weiskirchen R., Zimmermann H.W., Gassler N., Ginhoux F., Weber C., et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009, 50:261-274.
31. Tacke F., Alvarez D., Kaplan T.J., Jakubzick C., Spanbroek R., Llodra J., et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. JClin Invest 2007, 117:185-194.
32. Kallis Y.N., Forbes S.J. The bone marrow and liver fibrosis: friend or foe?. Gastroenterology 2009, 137:1218-1221.
33. Wynn T.A., Ramalingam T.R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012, 18:1028-1040.
34. Johnson M., Huyn S., Burton J., Sato M., Wu L. Differential biodistribution of adenoviral vector invivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum Gene Ther 2006, 17:1262-1269.
35. Zanger U.M., Hauri H.P., Loeper J., Homberg J.C., Meyer U.A. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci U S A 1988, 85:8256-8260.
36. Hintermann E., Holdener M., Bayer M., Loges S., Pfeilschifter J.M., Granier C., et al. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. JAutoimmun 2011, 37:242-253.
37. Ma Y., Bogdanos D.P., Hussain M.J., Underhill J., Bansal S., Longhi M.S., et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006, 130:868-882.
38. Manns M.P., Griffin K.J., Sullivan K.F., Johnson E.F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. JClin Invest 1991, 88:1370-1378.
39. Friedman S.L., Bansal M.B. Reversal of hepatic fibrosis-fact or fantasy?. Hepatology 2006, 43:S82-S88.
40. Muddu A.K., Guha I.N., Elsharkawy A.M., Mann D.A. Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic. Int J Biochem Cell Biol 2007, 39:695-714.
41. Ramachandran P., Iredale J.P. Liver fibrosis: a bidirectional model of fibrogenesis and resolution. QJM: Monthly J Assoc Physicians 2012, 105:813-817.
42. Puche J.E., Lee Y.A., Jiao J., Aloman C., Fiel M.I., Munoz U., et al. Anovel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice. Hepatology 2013, 57:339-350.
43. Thaci B., Ulasov I.V., Wainwright D.A., Lesniak M.S. The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget 2011, 2:113-121.
44. Liaskou E., Wilson D.V., Oo Y.H. Innate immune cells in liver inflammation. Mediators Inflamm 2011, 2012:949157.
45. Radaeva S., Sun R., Jaruga B., Nguyen V.T., Tian Z., Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006, 130:435-452.
46. Radaeva S., Wang L., Radaev S., Jeong W.I., Park O., Gao B. Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am J Physiol Gastrointest Liver Physiol 2007, 293:G809-G816.
47. Zhu J., Huang X., Yang Y. NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus. JImmunol 2010, 185:7480-7486.
48. Hintermann E., Bayer M., Pfeilschifter J.M., Luster A.D., Christen U. CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. JAutoimmun 2010, 35:424-435.
49. Eisenhardt M., Glassner A., Kramer B., Korner C., Sibbing B., Kokordelis P., et al. The CXCR3(+)CD56Bright phenotype characterizes a distinct NK cell subset with anti-fibrotic potential that shows dys-regulated activity in hepatitis C. PloS One 2012, 7:e38846.
50. Liu Q., White L.R., Clark S.A., Heffner D.J., Winston B.W., Tibbles L.A., et al. Akt/protein kinase B activation by adenovirus vectors contributes to NFkappaB-dependent CXCL10 expression. JVirol 2005, 79:14507-14515.
51. Kisseleva T., Uchinami H., Feirt N., Quintana-Bustamante O., Segovia J.C., Schwabe R.F., et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. JHepatol 2006, 45:429-438.
52. Scholten D., Reichart D., Paik Y.H., Lindert J., Bhattacharya J., Glass C.K., et al. Migration of fibrocytes in fibrogenic liver injury. Am J Pathol 2011, 179:189-198.
53. Pradere J.P., Kluwe J., De Minicis S., Jiao J.J., Gwak G.Y., Dapito D.H., et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells. Hepatology 2013.
54. Minagawa M., Kawamura H., Liu Z., Govindarajan S., Dennert G. Suppression of adenoviral gene expression in the liver: role of innate vs adaptive immunity and their cell lysis mechanisms. Liver Int 2005, 25:622-632.
55. Maher J.J. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis 2001, 21:417-426.
56. Barron L., Wynn T.A. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol 2011, 300:G723-G728.
57. Efe C., Ozaslan E., Purnak T., Ozturk R. Membranous glomerulonephritis associated with autoimmune hepatitis and primary biliary cirrhosis overlapsyndrome: a very rare condition. Eur J Gastroenterol Hepatol 2010, 22:1149-1150.